OptimizeRx Corp (OPRX) Stock Analysis

AI analysis of OptimizeRx Corp (OPRX)

Buy

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

Analyst Ratings (1)

+180.62% upside

Buy

1 Buy

0 Hold

0 Sell

Current: 8.67

Low

17.00

Average

24.33

High

32.00

B. Riley

Buy

$11

2026-09-29

B. Riley

2026-09-29

Price Target

$11

Buy

Stifel

Buy

$12

2026-08-13

Stifel

2026-08-13

Price Target

$12

Buy

B. Riley

Buy

$10

2026-05-13

B. Riley

2026-05-13

Price Target

$10

Buy

Lake Street

Buy

$11

2026-05-13

Lake Street

2026-05-13

Price Target

$11

Buy

Stifel

Buy

$14

2026-05-13

Stifel

2026-05-13

Price Target

$14

Buy

See All Ratings

Valuation Metrics

The current forward P/E ratio for OptimizeRx Corp (OPRX) is 6.95, compared to its 5-year average forward P/E of 43.69.

Forward P/E

Undervalued

5Y Average P/E

43.69

Current P/E

6.95

Overvalued

77.00

Undervalued

10.38

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

40.57

Current EV/EBITDA

47.11

Overvalued

84.25

Undervalued

-3.12

Forward P/S

Fair

5Y Average P/S

3.57

Current P/S

1.74

Overvalued

7.13

Undervalued

0.02

Alphio AI Price Scenarios for OPRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OPRX

$17.89

Scenario price

B

Base

Base · 50%OPRX

$16.60

Scenario price

B

Bear

Bear · 25%OPRX

$15.41

Scenario price

Whales holding OPRX

R

Rice Hall James & Associates, LLC

+ HoldingOPRX

+6.45%

3M Return

OPRX FAQ — answered by Alphio AI

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.